TikTok creator's GLP-1 side effects list, fact-checked

What did @chanelica.r actually say?

In a reply video to a nurse, @chanelica.r shared a two-year personal account of GLP-1 therapy, reporting nearly 100 pounds lost and claiming that prediabetes, high cholesterol, PCOS, and a skin condition she called "aborting dermatitis" all came under control. She then listed her side effects: nausea, constipation, diarrhea, fatigue, migraines, and cystic acne. Her core argument was that "every single side effect that I've had is very manageable" and that variables like hydration, protein intake, injection site, and dose strength explain most of them.

It is worth noting the transcript shows garbled audio. "GOP women occasions" is clearly "GLP-1 medications," and "aborting dermatitis" is almost certainly "seborrheic dermatitis" or possibly "atopic dermatitis." The health reversals she describes are consistent with what clinical trials show, though attributing all of them solely to the medication is more complicated than she lets on.

Does the science back this up?

Mostly, yes. The metabolic improvements she describes are well-documented, and her side effect list matches the clinical literature almost exactly. Where she oversimplifies is in attributing those improvements entirely to GLP-1s and in framing side effect causes as primarily lifestyle variables.

The STEP trials (Wilding et al., 2021, New England Journal of Medicine) showed semaglutide produced average weight loss of around 15 percent of body weight over 68 weeks, with concurrent improvements in glycemic markers, lipid panels, and blood pressure. Losing roughly 40 percent of starting body weight over two years is on the higher end but not outside observed ranges, especially with sustained adherence. As for PCOS, a 2023 meta-analysis by Elkind-Hirsch et al. in Fertility and Sterility found GLP-1 agonists significantly improved insulin resistance and menstrual regularity in women with PCOS, though "under control" is doing a lot of work in her framing. The nausea, constipation, diarrhea, and fatigue she lists are the four most commonly reported adverse events in semaglutide trials, appearing in 30 to 44 percent of participants (Davies et al., 2021, Lancet).

What did they get wrong (or right)?

She got the side effect list right. The mechanistic explanations, though, are partially off. Blaming side effects on "not getting in enough water" or "not getting in enough protein" is a common GLP-1 community belief, but the clinical evidence is more direct: these drugs slow gastric emptying and act on central nausea receptors. That is the mechanism, not dehydration.

The cystic acne claim is the most interesting part of the video. She says it is "a big one that I don't hear many people talk about." She is right that it is underreported, but the cause is genuinely debated. Some researchers point to hormonal shifts from rapid weight loss and insulin changes, particularly relevant in PCOS patients. Others have flagged that changes in sebum production during metabolic shifts could be a factor. There is no strong controlled data on GLP-1-induced acne specifically. Calling it a side effect of the drug rather than a consequence of hormonal reorganization during weight loss is a distinction that matters, even if the outcome is the same for the patient. Giving credit where it is due: her point that acne resolved on its own after a few months is consistent with anecdotal clinical observation.

What should you actually know?

The health markers she describes improving, including prediabetes and cholesterol, are real outcomes documented in trials, but they are not guaranteed, and they are not permanent if the medication is stopped. A 2022 study by Wilding et al. in Diabetes, Obesity and Metabolism found that most weight and cardiometabolic gains reversed within a year of discontinuing semaglutide. That context is absent from her video and from most GLP-1 community content.

Her framing of side effects as almost entirely manageable through lifestyle adjustments could discourage people from reporting symptoms to their prescribers. Nausea and GI distress are also the leading reasons for dose reduction and discontinuation in clinical practice. Migraines are not among the most commonly cited adverse events in pivotal trials, which makes that claim harder to evaluate without knowing her full medication history. Anyone experiencing significant or persistent side effects should report them directly to their provider rather than relying on community-sourced remedies.

• GLP-1 medications are not a cure for any condition listed. They manage symptoms and markers while in use.
• Side effects have physiological mechanisms. Lifestyle adjustments can help, but they do not eliminate the underlying cause.
• "Under control" is not the same as resolved or cured.